ASX-Dividend-Report-Banner

MGI Tech opens Customer Experience Center in Brazil to contribute to the advancement of genomics in Latin America

April 28, 2024 07:54 PM AEST | By Cision
 MGI Tech opens Customer Experience Center in Brazil to contribute to the advancement of genomics in Latin America
Image source: Kalkine Media

The laboratory has state-of-the-art technology to support medical research of clinical labs and healthcare institutions, improving precision diagnoses and treatments. The agricultural sector can also benefit

SÃO PAULO, April 28, 2024 /PRNewswire/ -- Contributing to the advancement of genomics in Latin America, MGI Tech Co. Ltd. (MGI), a company committed to building core tools and technology to lead life science, announced the launch of its Customer Experience Center (CEC) in Brazil.  

Commitment to Brazil healthcare

The goal is to provide a facility for clinical and research laboratories, hospitals, and universities to enhance learning and experience with genetic sequencing technology, applied in precision medicine, oncology, agrigenomics (application of the genome in agriculture) and metagenomics (collection of genomes of environmental microbial communities), among other segments.

"Genomic research has grown exponentially in the region. As the demand for next generation sequencing tests in cancer diagnostics and genetic screening increases, hospitals, clinics, laboratories and universities need to rely on supporting laboratories to improve their capabilities with affordable solutions faster sample processing speed and high data quality", says Carlos Carpio, Senior Commercial Director of MGI LATAM and General Manager of MGI Brazil.

"Our Customer Experience Center will be able to contribute significantly to the scientific development of the region by reducing sequencing costs, expanding clinical applications and, therefore, making precision diagnoses and treatments more accessible to the population", he adds.

The lab will also play a role as MGI Hub in Brazil, allowing the expansion of operations across Latin America. It demonstrates MGI's enduring dedication to broadening global genomics accessibility in this region. MGI has been operating in Latin Americas since 2019 and has already partnered with many clients, such as Fundação Oswaldo Cruz (Fiocruz) in Brazil, Biogenar in Argentina, Gencell in Colombia, Genos in Mexico and TCL Group in Chile.

In Brazil, MGI's technology also supports the largest Brazilian genomic sequencing project, which aims to sequence the complete genomes of thousands of patients with rare diseases and hereditary cancers, searching for genetic markers to track inherited diseases for early diagnosis. Coordinator of the genomic project, Dr. João Bosco de Oliveira Filho highlights MGI's technology: "I had a wonderful experience working with MGI's team. The technology is solid, the data quality is outstanding and the support is available when needed", he also welcomes the importance of the launch of the CEC: "Researchers and diagnostic laboratories need to stay up-to-date on available technologies to advance their studies and tests; therefore, it is very important to have a local support laboratory and service personnel".

State-of-the-art technology provided in the Lab

MGI operates in 100 countries and has other 9 Customer Experience Centers around the world. The Brazilian center, located in Brooklin Paulista, in São Paulo, will provide a place for clinical laboratories, universities, and hospitals to engage in demonstrations, enhancing their education and experience with the company's technology. Highly skilled professionals will lead certified training sessions, demonstrations, evaluations and local new application support.

CEC, with 270 m2, comprises four distinct areas: NGS (Next Generation Sequencing) lab, automation lab, BIT lab and engineering lab.

MGI's sequencing experience features the high throughput sequencer DNBSEQ-T7, high speed sequencer DNBSEQ-G99, the robust and flexible DNBSEQ-G400, and portable and easy-to-use sequencer DNBSEQ-E25*.  

At the automation lab, the company offers access to cutting-edge technology, with sample preparation system MGISP-100 and MGISP-960, high and low throughput automated nucleic acid extractor MGISP-384 and MGISP-NE32, and automated sample transfer processing system MGISTP-7000.

There are also bioinformatics products such as ZTRON Pro, a data processing platform and storage, and MegaBOLT, a bioinformatics analysis accelerator series.

Researchers and other professionals will be able to experience the range of end-to-end MGI solutions in the CEC São Paulo, as it is fully equipped to conduct genomics laboratory protocols.

CEC São Paulo is located at Avenida das Nações Unidas, 11633 – 15 floor – Brooklyn – São Paulo. Further information: [email protected].

*Certain sequencers can be used for research purposes only and not for use in any diagnostic procedures. Please consult MGI's local contactor for details.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.